Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 5/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 11/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15793648 | 1.00 | MGLL (0.43) | MGLLP2RX7HRH3SCN9AHCRTR2 | |
| SCHEMBL15793961 | 1.00 | MGLL (0.43) | MGLLP2RX7HRH3SCN9AHCRTR2 | |
| SCHEMBL15793460 | 1.00 | MGLL (0.43) | MGLLP2RX7HRH3SCN9AHCRTR2 | |
| SCHEMBL15793298 | 1.00 | MGLL (0.43) | MGLLP2RX7HRH3SCN9AHCRTR2 | |
| SCHEMBL14814809 | 0.95 | MGLL (0.48) | MGLLP2RX7 | |
| SCHEMBL14814656 | 0.88 | MGLL (0.54) | MGLLP2RX7HCRTR2 | |
| SCHEMBL15794061 | 0.87 | MGLL (0.40) | MGLLP2RX7HCRTR2 | |
| SCHEMBL15794234 | 0.87 | MGLL (0.40) | MGLLP2RX7HCRTR2 | |
| SCHEMBL15793822 | 0.87 | MGLL (0.40) | MGLLP2RX7HCRTR2 | |
| SCHEMBL15794285 | 0.87 | MGLL (0.40) | MGLLP2RX7HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2931727-A1 | DIAZEPINE DERIVATIVES USEFUL AS CALCIUM CHANNEL BLOCKERS IN THE TREATMENT OF PAIN | Abbvie Inc. (US) | 2015-10-21 | — | — | EP | disclosed |
| WO-2014093337-A1 | DIAZEPINE DERIVATIVES USEFUL AS CALCIUM CHANNEL BLOCKERS IN THE TREATMENT OF PAIN | ABBVIE, INC. (US) | 2014-06-19 | — | — | WO | disclosed |